This research is designed to determine if experimental treatment with PARP1 inhibitor, VB15010 is safe, tolerable, and has anti-cancer activity in patients with advanced solid tumors.
Age ≥ 18 at the time of screening;
Histological or cytological confirmation of advanced malignancy ;
Progressive cancer at the time of study entry;
Adequate organ and marrow function as defined by the protocol;
Major surgery within 4 weeks of the first dose of study treatment.
Spinal cord compression or brain metastases unless asymptomatic, treated and stable and not requiring continuous corticosteroids at a dose of >10mg prednisone/day or equivalent for at least 4 weeks prior to start of study treatment. Patients with leptomeningeal carcinomatosis are excluded.
Patients with myelodysplastic syndrome/acute myeloid leukaemia or with features suggestive of myelodysplastic syndrome (MDS)/acute myeloid leukaemia (AML).
Zhejiang Yangli Pharmaceutical Technology Co., Ltd.
Lead sponsor
Shandong Cancer Hospital and Institute
Collaborator